PP405 is a new hair loss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hair follicle stemcells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.
PP405 may damage hair follicles if used long-term, suggesting cycling might be necessary. Combining it with finasteride could help maintain hair growth.
The conversation discusses concerns about the potential risk of cancer from creating new hair follicles through microneedling, due to stemcell division. Specific treatments mentioned include microneedling, caffeine-containing anti-hair loss shampoos, and other unspecified topicals.
MCL-1 is important for hair follicle stemcell survival, but its impact on human hair regrowth is unclear. Minoxidil and finasteride are the main treatments, with doubts about new discoveries leading to effective human solutions soon.
Hair loss treatments like Minoxidil, finasteride, and stemcell therapies exist, but a complete cure is hindered by genetic complexity and market dynamics. Cloning hair follicles is considered a potential solution, but it's currently not feasible.